Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 9, 2026Archives of cardiovascular diseases

The relationship between cardiac structure, function, and clinical outcomes, and the impact of Vutrisiran from the HELIOS-B trial

View Full Paper
Ask AI
Bookmark
Share

Authors

KJKarola JeringMFM. FontanaHSH. Skali

Discussion

Loading...

Member takes

Overview

Cardiac structure and function relate to clinical outcomes, showing the effects of vutrisiran in the HELIOS-B trial.

Key Points

  • The research aims to examine how cardiac structure and function influence clinical outcomes, and to assess the effects of vutrisiran treatment.
  • Analyzed data from the HELIOS-B trial involving cardiac assessments and clinical evaluations.
  • Evaluated relationship between cardiac structure, function, and outcomes using statistical analyses.
  • Investigated the effects of vutrisiran on cardiac parameters.
  • Cardiac structure and function significantly correlated with clinical outcomes.
  • Vutrisiran treatment showed favorable effects on certain cardiac parameters.
  • Findings highlight the importance of monitoring cardiac changes in clinical settings.

Cite This Study

Jering et al. (2026) studied this question.

synapsesocial.com/papers/6961359d766f0a95ea6adb5bhttps://doi.org/10.1016/j.acvd.2025.10.089
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B2025 · 1 citations
  2. 2Impact of structural cardiology program on clinical characteristics and outcomes of cardiac surgery patients2026
  3. 3Evaluating the role of mavacamten in symptomatic non-obstructive hypertrophic cardiomyopathy: the ODYSSEY-HCM trial2025
  4. 4Advances in Clinical Cardiology 2025: A Summary of Key Clinical Trials2026
  5. 5Impaired myocardial work in heart failure with improved ejection fraction: A post hoc analysis from the CATHEDRAL-HF trial2025